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The current trends to postpone motherhood and the increase in demand for assistance in reproductive medicine highlight the
need for seeking guidelines for the establishment of individualized treatment protocols. Currently available ovarian reserve tests
do not provide suﬃcient evidence to be solely considered ideal, but they may occupy important place in initial counseling,
predicting unsatisfactory results that could be improved by individualized induction schemes and reducing excessive psychological
and ﬁnancial burdens, and adverse eﬀects. In this paper, we revise the role of hormonal basal and dynamic tests, as well as
ultrasonographic markers, as ovarian reserve markers, in order to provide embasement for propaedeutic strategies and their
interpretation in order to have reproductive success.
1.Introduction
Considering modern trends of maternity postponement
[1] and the increasing demand for assisted reproduction
technologies (ART), the evaluation of functional ovarian
reserve has arisen in an attempt to better advise interested
couples, helping physicians in the inference of follicular
response and success rates, and guiding the elaboration
of individualized stimulation protocols, with a reduction
of emotional and ﬁnancial burdens of hard and stressful
therapeutic processes. In this context, the identiﬁcation
of women with a lower reproductive potential is a great
challenge for reproductive medicine specialists.
Sharara and Scott emphasized that an ideal ovarian
reserve parameter should be easily measurable, minimally
invasive, and inexpensive and should have good predictive
values [2]. Serum and ultrasonographic markers have been
tested to infer the gonadal reserve of infertile women, but
none of them has been proven to conﬁdentially reﬂect the
complex follicular dynamics or to be strongly correlated
with the size and/or quality of primordial follicles remaining
in the gonads after each wave of follicular growth. In
other words, those tests do not ideally reﬂect the pool
of unrecruited follicles, which may be responsible for the
continuity of ovulatory cycles and, therefore, for the long-
term reproductive potential [3–7].
In this paper, we present a review of the literature,
providing a rationale on the applicability of age and men-
strual pattern as clinical markers, and the most commonly
used tests for the evaluation of ovarian reserve in infertile
women. Tests were divided into static (endocrine and ultra-
sonographic tests performed in the early follicular phase)
and dynamic (endocrine tests assessing ovarian response to
exogenous gonadotropic stimulus).
2.ClinicalMarkers
2.1. Age. Age is considered to be the single most important
factorindeterminingqualityandquantityofovarianreserve.
It is well known that both the quantity and quality of ovarian
follicles signiﬁcantly decrease as a woman advances in age
and that many women who postpone maternity may be
infertile at the time they are willing to become pregnant.
Fecundability signiﬁcantly declines since the early 30s [8],2 ISRN Obstetrics and Gynecology
and the prevalence of infertility increases signiﬁcantly after
the age of 35 years; about 99% of patients are expected to be
infertile with 45 years of age [9].
Fertility decline can be attributed to numerous events
associated with advancing age, including changes in oocyte
quality, frequency and eﬃciency of ovulation, sexual func-
tion, uterine diseases, and the risk of pregnancy complica-
tions, such as gestational diabetes and hypertensive disease.
Also, genetic factors, smoking, infections, and adnexal
surgeriesshallbedeterminantsofdiminishedovarianreserve
in older women [10].
In historical cohorts, the rates of infertility among
women who were married at the age groups of 20–24, 25–29,
30–34, 35–39, and 40–44 years were 6%, 9%, 15%, 30%, and
64%, respectively [9]. Likewise, the probabilities of clinical
pregnancy after intercourse on fertile days in women age
groups of 19–26, 27–34, and 35–39 years were approximately
50%, 40%, and 30%, respectively, with partners in the same
age groups [11].
Women undergoing artiﬁcial insemination with donor
sperm because of male factor for infertility (azoospermia)
presented with lower rates of conception or needed more
cycles to achieve it after 35 years of age [12]. Similar
results were obtained in in vitro fertilization (IVF) cycles
using nondonor fresh eggs; birth rates for age groups of
<35, 35–37, 38–40, 41-42, and>42 years were 36%, 28%,
18%, 10%, and 4% per cycle, respectively [13]. Data from
Red Latinoamericana de Reproducci´ on Asistida demonstrated
a signiﬁcant reduction of pregnancy rates per IVF cycle
with follicular aspiration: 38% in women 30–34 years, 31%
in women 35–39 years, and 16% in older patients [14].
Furthermore, studies have shown that women of advanced
maternal age unable to achieve pregnancy through IVF are
able to conceive using donor oocytes from younger women
[15].
We have recently reinforced previous studies conclusions
that ovarian response to exogenous stimulus for ART is
signiﬁcantly associated with age and, also, its capacity to
predict the occurrence of poor response and pregnancy
in intracytoplasmic sperm injection (ICSI) cycles. In our
study,thenumberofpreovulatorydominantfolliclesandthe
total number of oocytes and mature oocytes yielded were
signiﬁcantly higher between women with≤35 years of age
[16].
2.2. Menstrual Pattern. Menstrual cycle length (MCL) is
supposed to be primarily determined by the rate and quality
of follicular growth, and, thus, the duration of the follicular
phase; in general, menstrual cycles range from 23 to 32
days [17] and exhibit a mean interval of 28 days. This
pattern is commonly expected to be fairly persistent until
the late 40s, but a gradual shortening in cycle length may
initiate in the late 30s, in parallel with higher serum levels of
follicularstimulatinghormone(FSH)andlowerserumlevels
of inhibins [18].
The age-dependent shortening of MCL is suspected to be
relatedwithshortenedfollicularphases;thereisevidencethat
the mechanism behind it should, in part, involve diminished
production of inhibin-B by a small number of antral follicles
and a consequent precocious increase of FSH secretion [19,
20]. Such a hypothesis gains force from the demonstrated
correlation between MCL and the antral follicle count (AFC)
during ultrasonographic evaluation [21].
According to the study of Brodin et al., conception
rate was signiﬁcantly reduced among women with MCL
shorter than 30 days and the adjustment for other potential
predictors of fertility, like age, had not appreciably changed
such an eﬀect. Also, MCL had signiﬁcant association with
ovarian response to gonadotropin stimulus and embryo
quality in IVF/ICSI cycles, and, even if the interference of age
is excluded, pregnancy rates are almost twice as high among
women with cycles>34 days when compared with those with
cycles<26 days [21].
3.EndocrineStaticMarkers
3.1. Follicle-Stimulating Hormone. Early follicular phase
(basal) FSH is the most studied and used endocrine test
in determining ovarian reserve [6, 22]. Historically, combi-
nation of basal FSH and age was found to be better than
age alone in predicting IVF outcome. Many IVF centers,
then, continue to rely on basal FSH serum measurements,
notwithstanding limitations like great variability in serum
FSH levels within and between menstrual cycles, interference
of external factors such as smoking [23], and disparities
between assays [24].
van der Steeg et al. studied predictive value of basal
FSH for spontaneous pregnancy occurrence in ovulatory
subfertile women younger than 40 years and observed
reduced chances when the levels exceeded 8IU/L, whereas
no association could be determined for lower levels [25]. In
a recent prospective study, Haadsma et al. pointed basal FSH
and AFC as signiﬁcant predictors of spontaneous pregnancy
[26].
The accuracy of FSH in predicting poor response to
ART stimulation has been considered to depend on the
identiﬁcation of very high serum thresholds [6]. Including
212 patients submitted to IVF cycles, Ashraﬁ et al. observed
that women with FSH levels≥15IU/mL had fewer aspirated
oocytes and a larger number of cancelled cycles than
women with lower levels, with no signiﬁcant diﬀerence
in gonadotropin doses administered [27]. Creus et al.
also demonstrated mean FSH serum concentrations to be
signiﬁcantly higher among patients with cancelled ART
cycles, which were independent from other variables, such as
age and inhibin-B [28]. In the study of Al-Azemi et al., FSH
was a good predictor of poor oocyte yield and only AMH
presented a better performance for that purpose [24].
Regarding pregnancy occurrence, Klinkert et al. sug-
gested that it was less frequent among women with FSH
levels≥15IU/L when compared to those with lower levels,
but with no statistical signiﬁcance [29]. Also, it was recently
demonstrated that pregnancy rates in women aged<35
years with elevated basal FSH were higher than those of
older women with normal levels of the hormone [30],
reinforcing age as a main ovarian reserve marker. In a
previous study, van Montfrans et al. had already suggested
that determination of basal FSH should not be decisive toISRN Obstetrics and Gynecology 3
the initial management of infertile women with clinically
normal cycles, once pregnancy occurred in about half the
women with elevated serum levels [31].
FSHcontinuestobeaninterestingtestonovarianreserve
investigation, since it is an easily accessible and low-cost
marker, and that could be useful in pretreatment evaluation
of speciﬁc groups of infertile women, such as those carrying
anovulatory cycles [31], endometriosis [32] or in patients
over 35 years of age [33]. As it was recommended by Luna
et al. [30], we believe that more careful counseling shall
be provided for patients aged ≥35 years, who are more
susceptible to lower ovarian response to stimulation and
higher rates of ART cancellation. That said, high FSH levels
should not be used to exclude women from proceeding with
ART once adequately counseled.
3.2. Inhibin-B. Inhibins are glycoprotein hormones of the
superfamily of transforming growth factors β (TGF-β)
secreted by granulosa and theca cells [34]. Inhibin-B inhibits
pituitary FSH secretion [35] and paracrine action on devel-
oping follicles, stimulated by the association of FSH itself
with insulin-like growth factor I [36, 37]. Investigation on
infertile patients 24–40 years of age demonstrated signiﬁcant
negative correlation between basal inhibin-B and FSH, and
signiﬁcant positive correlation between basal inhibin-B and
AFC [38].
In accordance with that, Seifer et al. demonstrated that
women with declining ovarian responsiveness and poor
outcomes in ART presented with diminished basal serum
concentrations of inhibin-B, in spite of nonelevated day
3 FSH levels. Furthermore, greater estrogen responses and
higher amounts of oocytes were obtained after stimula-
tion of women with serum inhibin-B levels≥45pg/mL,
whereascancellationswerethreetimesmorefrequentamong
those with lower levels [39]. Signiﬁcant correlations were
either found between the number of oocytes retrieved and
serum inhibin-B concentration, and all patients with serum
inhibin-B levels>100pg/mL had>6 oocytes yielded [40]. In
the study of Pe˜ narrubia et al., day 5 inhibin-B was associated
with live-birth rates after IVF with 68.71% sensitivity and
88.51% speciﬁcity, which was statistically signiﬁcant and
stronger than any other variable investigated [41].
Other studies, however, did not recommend the use of
inhibin-B alone as a reliable predictor of ovarian reserve [42,
43]. McIlveen et al. observed signiﬁcant intercycle variability
in inhibin-B concentrations [44]. The systematic review of
Broekmans et al. [6] was emphatic in counseling clinicians
to be aware of the high rate of false positives in routine
determination of basal inhibin-B and cautiously analyze
exclusion of patients from IVF programs with base on its
levels. Those authors stated that even using very low inhibin-
B levels, accuracy of the test in predicting poor response
was only modest when compared with the other available
markers, even though it can be used as a tool for counseling
infertile couples.
3.3. Estradiol. Basal estradiol (E2) levels may provide addi-
tional useful information for the evaluation of ovarian
reserve. Early elevations in serum E2 are understood as a
consequence of the advanced follicular development and
early selection of a dominant follicle observed in older
cycling women that are driven by rising FSH levels [18].
HigherratesofcancelledARTcycleshavebeendemonstrated
with E2 levels <20pg/mL or ≥80pg/mL [45]. Measurement
ofbothFSHandE2oncycleday3may,thus,helptodiminish
the incidence of false-negative tests based on measurement
of FSH alone; when both markers are precociously elevated,
poor ovarian response is likely to occur [18].
However, other studies favorable to the use of E2 as an
ovarian reserve marker have been incapable to correlate it to
follicular development or demonstrate its ability to predict
the occurrence of pregnancy [45–48]. Fic ¸icioglu et al. have
also demonstrated similar basal E2 levels in serum of good
and poor responders to gonadotropic stimulus in ART cycles
[49].
E2 may be used to guide the clinician as to whether
the stimulation with gonadotropins can be started, but it
does not have value as IVF prognostic tool. Considering
the low predictive accuracy and the lack of high sensitivity
and speciﬁcity cutoﬀ levels [6], its role as a determinant
for couples inclusion in ART programs should, therefore, be
evaded.
3.4. Anti-M¨ ullerian Hormone. Anti-M¨ ullerian hormone
(AMH), also referred to as M¨ ullerian-inhibiting substance, is
a glycoprotein hormone of the TGF-β superfamily expressed
by granulosa cells as soon as the primordial follicles are
recruited [50]; its expression is maintained until the follicles
reach about 6mm in diameter, when preantral/initial antral
folliclesareselectedfordominance[51]andfolliculargrowth
follows controlled by FSH action [52].
The biological activity of AMH in women is not com-
pletely understood, but data along the last years suggest
that it may act as a modulator of follicle recruitment and a
regulator of ovarian steroidogenesis [50, 53]. AMH is known
tohaveaninhibitoryeﬀectonthepoolofprimordialfollicles,
acting on pregranulosa cells in order to limit the number
of recruitable follicular units and, later, as a decisive factor
in permitting the FSH-dependent growth of ovarian follicles
[52–56].
From the foregoing provisions, AMH determination has
been proposed in clinical practice for the prediction of
ovarian reserve. AMH is considered to be a marker that
can estimate the quantity and activity of retrievable follicles
in early stages of maturation, thus being more reliable
for the prediction of ovarian response and reproductive
potential [43, 50, 52, 57–60]. Other studies also supported
this aﬃrmative by demonstration of a decreasing rate in
circulating AMH levels with age [61–63].
Compared to FSH, inhibin-B, and E2, AMH has the
advantage of reduced variability of its serum concentrations
along the menstrual cycle [5, 64, 65] and consequent mallea-
bility regarding the time of its determination. Mean values of
1.4 ± 1.1ng/mL, 1.43 ± 1.08ng/mL, and 1.35 ± 1.02ng/mL
were measured in follicular, periovulatory, and midluteal
phases, respectively [64]. AMH stable serum levels were
also demonstrated by other studies [52–54]; Tsepelidis et al.4 ISRN Obstetrics and Gynecology
obtained a mean of 2.4 ± 1.1ng/mL along the menstrual
cycle in normoovulatory patients [66]. The reproducibility
of AMH between cycles was also demonstrated; lower
variations in serum levels between consecutive cycles were
found for AMH when compared with those detected for
FSH, inhibin-B, and E2, or the antral follicle count (AFC),
a m o n gi n f e r t i l ew o m e na g e d2 0t o4 0y e a r so l d[ 5].
In ART, van Rooij et al. detected reduced preinduction
AMH levels and AFC in poor responders (women with
canceled cycles or from whom fewer than four oocytes were
yielded) compared to women with a good response to the
exogenous stimulus. There was also a strong correlation
between the two markers, who were found to be important
predictors of the response [57]. Recent data were obtained
in order to evaluate the eﬃcacy of AMH levels and AFC to
predict IVF outcomesand demonstratedthat AMH is at least
as eﬃcient as AFC to predict high ovarian response, with
regard to its ability to identify poor responders [67–69].
In a prospective evaluation of previous poor responders
(fewer than 4 follicles with a diameter>15mm) older than
3 8y e a r sw i t hab a s a lF S H >10UI/L, AMH was considered
to be the best single marker of the ovarian response to
the exogenous stimulus, once patients with incomplete ART
cycles presented with signiﬁcantly reduced serum levels [70].
In the study by Fic ¸icioglu et al., serum AMH levels were sig-
niﬁcantly higher in women with adequate ovarian response
to exogenous stimulus (0.67 ± 0.41pg/mL) compared with
poor responders (0.15 ± 0.11pg/mL) [49], supporting the
results of previous studies [57, 64]. In the prediction of low
number of oocytes yielded, basal AMH presented the largest
area under the curve (AUC = 0.92) among all variables
tested,followedbyAFC(AUC = 0.78)andage(AUC = 0.63)
[49].
Fadini et al. conﬁrmed AMH serum concentration as a
highly eﬀective predictor of the number of retrieved oocytes
and, then, instrumental for the recognition of women
with reduced ovarian function and those suitable for an
oocyte in vitro maturation (IVM) treatment. Actually, AMH
allowedauthorstoidentifycyclesabletoproducesatisfactory
amounts of oocytes and, then, reduce the eﬃciency gap
between IVM and conventional IVF [71].
The lack of a consensual cutoﬀ combining satisfactory
sensitivity and speciﬁcity for routine use continues to
represent a considerable drawback. Muttukrishna et al.
demonstrated 87% sensitivity and 64% speciﬁcity of AMH
in the prediction of response and cancellation in ART, for
ac u t o ﬀ of 0.2ng/mL [60]. La Marca et al. ratiﬁed the use of
AMHforthepredictionofapoorresponsebydemonstrating
80% sensitivity and 93% speciﬁcity in AR cycles when a
threshold of 0.75ng/mL was considered [72]. An interesting
study reported AMH value of 1.26ng/mL by which 88% of
poor responders should be identiﬁed (patients with less than
5oocytesretrieved)instandardIVFcycles[73],andasimilar
cutoﬀ (1.28ng/mL) was determined as a guidance to decide
the appropriateness of oocyte IVM as a treatment (at least 5
oocytes retrieved) [71].
Irez et al. have recently demonstrated the signiﬁcant
association between basal AMH serum concentration with
the total number of oocytes and AFC, inhibin-B and FSH
levels, oocyte quality and embryo development in intracy-
toplasmic sperm injection (ICSI) cycles. Also, the authors
observed that early embryo cleavage rate was signiﬁcantly
higher among patients with AMH serum levels between
1.40ng/mL and 4.83ng/mL [74], supporting the hypo-
thetical association of AMH with implantation rates [75–
77]. Likewise, Arabzadeh et al. have recently demonstrated
positivecorrelationbetweenserumbasalAMHlevelsandthe
number of oocytes retrieved and the percentage of mature
oocytes, but signiﬁcance was also not reached in correlation
between the marker and implantation rate [78].
Attempts have also been made to correlate serum AMH
levels with the occurrence of pregnancy following ART. Val-
ues higher than 2.7ng/mL were associated with higher rates
of implantation and pregnancy (although not signiﬁcant),
and the levels measured on the day of human chorionic
gonadotropin (hCG) administration were superior (AUC =
0.647) to those of basal FSH regarding the prediction of
embryo quality [22]. Recent studies carried out to determine
the value of AMH as a marker of the response to the stimulus
were unable to establish its value as a predictor of pregnancy
[48, 73].
Finally, a recent systematic review pointed AMH as a
useful test in the prediction of poor response and cycle
cancellation and also of ovarian hyperstimulation in ART.
The authors found it to be better than patient’s age in
predicting ovarian response to exogenous stimulus, with
similar performance only for AFC [79].
Based on the favorable results reported and on the
proven signiﬁcant correlation with important variables such
as AFC and the quantity of matured or aspirated oocytes,
we believe in a promising future for AMH as an important
clinical marker in the assessment of female infertility. At
this moment, poor response can be associated with AMH
serum levels<1ng/mL, normal response with levels from 1
to 4ng/mL, and high response with levels>4ng/mL[60, 69,
72, 79, 80].
4.EndocrineDynamicTests
4.1. Clomiphene Citrate Challenge Test. Clomiphene citrate
challenge test (CCCT) was ﬁrst described by Navot et
al. In the original study, 100mg clomiphene citrate was
administered to women aged ≥35 years from days 5–
9 of the menstrual cycle. FSH, LH, and E2 levels were
primarily determined on cycle days 2-3, and response was
determined on cycle days 9–11. Diminished ovarian reserve
was determined by day 3 FSH >14.9mIU/mL or day 10
FSH> day 3 FSH [81].
CCCT was found to predict the occurrence of less
than 6 aspirated oocytes in IVF cycles, with an expressive
area under the ROC curve (AUC = 0.88) among women
aged 18 to 39 years [82]. Years before, Corson et al. had
associated prognostic CCCT value in determining response
of women >35 years of age or those with previous poor
response, although weak correlations with other tests limited
conclusions [42]. In contrast, previous data had shown
a higher sensitivity of basal FSH alone for prediction of
follicular development [83].ISRN Obstetrics and Gynecology 5
In the recently published systematic review of Mahesh-
wari et al., values of likelihood ratios of positive and
negative CCCT did not provide suﬃcient evidence for
prediction of nonpregnancy or ART cycle cancellation in
20 eligible studies. Although CCCT was fairly done in a
uniform manner, the absence of standardized abnormal test
deﬁnitions prevented strong conclusions and authors could
not support its use as a prognostic tool with the achieved
l e v e lo fe v i d e n c e[ 84].
4.2. Gonadotropin Analogue Stimulation Test. Identiﬁcation
and measurement of FSH, LH, inhibin-B, and E2 levels
ﬂare-up within 24 hours of administration of gonadotropin
analogue are the end points of gonadotropin analogue
stimulation test (GAST) [85].
Signiﬁcant positive correlations between ovarian
response and the sum of basal and poststimulus inhibin-B
levels, or the increase in E2 levels after stimulus, have been
demonstrated [86]. Also, McIlven et al. detected a predictive
value of elevated E2 levels after GAST for the cancellation of
ART cycles among women>39 years of age, with previous
poor response or elevated basal FSH [44]. Hendriks et al.
also recognized some value of the test for that purpose or as
a predictor of pregnancy but reported that it did not show a
better clinical performance than the determination of basal
inhibin-B or AFC [87].
As a matter of fact, a wide variety of gonadotropin-
releasing hormone (GnRH) analogue doses and administra-
tiontiming,hormonestestedininitialandﬁnalsamples,and
their thresholds were not standardized in literature on GAST
[84]. Just like the CCCT, GAST should not be an eligible
ovarian reserve test in clinical routine, with the present body
of evidence.
4.3. Exogenous FSH Ovarian Reserve Test. The exogenous
FSH ovarian reserve test (EFORT) is based on the increase
of E2 and inhibin-B 24 hours after the administration of
300IUofrecombinantFSH(rFSH)oncycleday3,inorderto
determine the functional condition of the ovarian apparatus
[82].
Increased levels of E2 and inhibin-B after EFORT had
been postulated to present the best predictive values for the
numberofovariandominantfolliclesobtainedafterstimulus
[88], mainly when basal FSH levels were associated with this
increase [82]. However, it has been recently demonstrated
that, as well as with CCCT and GAST, methodology for
EFORT is far from uniform parameters [84] and this lack
of pattern maintains the test among those that should be
avoided in determining ovarian reserve for infertile patients.
5.Ultrasonographic Markers
5.1. Antral Follicle Count. Pre-ART ultrasonographic AFC
has been shown to be an excellent predictor of ovarian
reserve and response, with signiﬁcant superiority in relation
to other markers [89–91]. Studies also demonstrated signif-
icant correlations between AFC and commonly performed
serumovarianreservetests[92],andbetweenAFCandAMH
[50, 52]. In a recent systematic review, AFC alone was as
accurate as diﬀerent combinations of clinical, biochemical
and other ultrasonographic markers in predicting IVF
response [91].
According to the study of Muttukrishna et al., AFC
should allow identiﬁcation of poor response with 89%
sensitivity, in spite of low speciﬁcity [60], and other authors
admit its importance as a screening test for infertile couples
[6]. Elgindy et al. assessed AFC with up to 10mm in mean
diameter and found 10.1 ± 3.0 and 5.7 ± 1.0 antral follicles,
respectively, for normal and poor responders [64].
According to Maseelall et al., women with AFC≥ 11
(follicles measuring between 2 and 10mm present on both
ovaries) are more likely to obtain a live birth if compared
with those with less antral follicles, who should be advised
about the increased risks of miscarriage, cycle cancellation,
higher doses of gonadotropins, and fewer oocytes yielded
[93]. Despite those results, a recent meta-analysis supported
good expectations for women with less antral follicles, since
98.7% of women who got pregnant presented AFC ≥ 4a n d
cyclecancellationrateamongwomenwithatleastfourantral
follicles was 2.5% (95% CI, 1.8–3%) [94].
Special attention has been given to small antral follicles.
In the study of Klinkert et al., normal response to stimulus
for ART was signiﬁcantly elevated for women with AFC ≥
5 units with mean diameter up to 5mm [29], and Haadsma
et al. demonstrated signiﬁcant correlation between follicles
with up to 6mm and ovarian reserve endocrine tests, in
contrast to that observed with larger follicles, which were
consistent only with ovarian volume and serum levels of
inhibin-B. Also, authors postulated the negative interference
ofadvancedageonsmallantralfolliclescount,whilethepool
of larger units should remain unchanged until the middle of
ﬁfth decade of life [92].
Results from literature seem to converge to recognition
of the importance of AFC as a predictor of ovarian response.
This is why Almog et al. proposed AFC normograms
according to age of infertile women [95], which, for instance,
still need validation on longitudinal studies, but may oﬀer
additionalinformationonprotocolsindividualizationstrate-
gies.
However, due to 2.6% sensitivity to predict nonpreg-
nancy and 66.7% sensitivity to predict cycle cancellation
[94], AFC must not be used as a criterion for ART exclusion,
but as a tool for counseling on the low probability of
achieving pregnancy and determining individualized treat-
ment protocols in IVF cycles. Since endovaginal ultrasound
evaluation is normally performed during the investigation of
infertile women, we believe that AFC should be deﬁnitely
included as a routine test of gonadal reserve in pre-ART
evaluation.
5.2. Ovarian Volume. Opinions are divided on considering
ovarian volume (OV) as an adequate gonadal reserve test.
Syrop et al. studied women aged 23–46 years undergoing
ART, associating diminished number of oocytes yielded
and pregnancy rates with decreased ovarian volumes [96].
Recently, the study of Gibreel et al. observed 92.9% (IC 95%,
86.9–96.7%)and91.7%(IC95%,88.5%–94.2%)speciﬁcities
for prediction of nonpregnancy and cycle cancellation,6 ISRN Obstetrics and Gynecology
respectively, with a 3.0mL cutoﬀ [94]. Finally, signiﬁcant
correlations had been previously found between reduced
ovarian measures, increased age, and elevated serum FSH
[97].
However, Elgindy et al. did not observe OV diﬀerences
between young women with normal and poor response
in ART (means of 4.1 ± 0.66mL and 3.36 ± 0.71mL,
resp.) [64], and McIlven et al. reached similar results
when evaluating women at high risk for cycle cancellation
[44]. The review of ten well-designed studies on ovarian
volume for that purposes concluded that OV presented little
applicability in the prediction of poor response or pregnancy
[98], as did Broekmans et al. in a previous study [6].
Some studies show concern about the use of OV as a
test of ovarian reserve and raised doubts on its reliability
being evaluated by two-dimensional ultrasound [99, 100],
leading some authors to recommend assessment by three-
dimensional ultrasound in order to minimize interobserver
variability [101–103]. Thus, OV alone should not be consid-
ered as a predictor of ovarian reserve, but we believe that
because of its easy performance, it may be included as a
routine in diagnostic procedures, adding information to the
patient medical records and providing data for further study.
5.3.OvarianBloodFlow. Ovarianbloodﬂow(OBF)hasbeen
extensively assessed in natural and stimulated reproductive
cycles [104] and negative correlation between age and
presovulatory perifollicular blood ﬂow [105]. The study of
Shrestha et al. supported such an aﬃrmative by demonstrat-
ing high pregnancy rate among women who presented with
highly vascularized follicles in early follicular phase [106].
In spite of the foregoing, a recent meta-analysis assessed
OBF as a predictor of IVF outcomes, but clinical value was
unclear, because of diﬀerent ﬂow-derived predictors used in
literature [94]. This is why ovarian vascular ﬂow may not
be used to determine inclusion of infertile couples in ART
programs or to infer its results.
6. Discussion
The main purpose of ovarian reserve evaluation, especially
before ART, is to identify women with poor ovarian reserve
for their chronological age. This is why age must always
be the ﬁrst marker to be considered in ovarian reserve
assessment. Older women may beneﬁt from ovarian reserve
tests since they can help clinicians to ﬁnd out acceptable
chances of pregnancy through IVF. Younger women with
altered tests should be ﬁrst classiﬁed as potentially poor
responders and must gain beneﬁts from individualized
stimulation protocols by quantitative estimative of the pool
of FSH-sensitive follicles [6].
The best ovarian reserve test should be able to identify
women whose chances of spontaneous pregnancy would be
sodiminishedthatitwouldbeappropriatetosubmitthemto
therapeutic ovarian stimulation or to identify women whose
chances of pregnancy after ART would be so close to zero
that it would not be justiﬁed to submit them to the potential
adverse eﬀects of exogenous gonadotropin stimulus.
Unfortunately, currently available tests do not provide
suﬃcient evidence to be considered ideal and, until new
studies provide more consistent results, directly submitting
women to ovarian stimulation for an IVF cycle has been
shown to be an adequate strategy in order to determine
follicular patrimony and female reproductive potential.
Basal ovarian reserve markers (endocrine or ultra-
sonographic) have deﬁnite advantages over dynamic ones,
regarding practicability, lower costs, and less side eﬀects.
Basal FSH, E2, and inhibin-B have been classically used to
infer gonadal function, but AMH and AFC may possibly
be the only static markers that can potentially assess the
follicular reserve as a whole, in quantity and quality.
Dynamic endocrine tests are, therefore, usually more
exceptions than rules in infertile women evaluation, once
their routine use involves elevated costs and the potential
adverse eﬀects of exogenous stimulation without a direct
relation with a real attempt to obtain a pregnancy. Thus,
those tests should be reserved for exceptional cases in which
the estimated risks of hyperstimulation should carefully be
considered.
Since no study succeeded in selecting an ovarian reserve
marker with satisfactory sensitivity and speciﬁcity alone,
multivariate evaluation models have been proposed for a
better estimate of functional gonadal capacity. In fact, a
recent meta-analysis concluded that several combinations
were similar to AFC alone to predict poor response to
IVF stimulation [91], but no study considering the com-
bination of AMH and AFC, which are currently being
extensively investigated in the evaluation of ovarian reserve,
was included. More studies evaluating this combination and
others will be necessary to rule out the use of multivariate
evaluation models in the assessment of ovarian reserve.
Finally, it is important to point out that ovarian reserve
evaluation for speciﬁc groups of infertile women, such
as those with endometriosis, hyperandrogenic anovulation,
autoimmune diseases, or endocrine-metabolic disorders, has
beenpoorlyinvestigated.Wehavedemonstratedasigniﬁcant
reduction in the total number of oocytes and morphologi-
cally mature oocytes aspirated after the exogenous stimulus
for ART in infertile women with endometriosis compared
with controls, in spite of that no signiﬁcant diﬀerences were
found in the level of basal AMH, E2, and AFC or in follicular
growth after the stimulus [32]. In a recent publication, we
have also shown that AMH was the only individual marker
with a signiﬁcant ability for determination of poor response
in endometriosis patients with 87.5% sensitivity and 73.7%
speciﬁcity, for levels ≤1.45ng/mL [107].
In order to reduce limitations due the scarcity of strong
evidence on ovarian reserve evaluation, future research
is expected to clarify the predictive value of tests, with
special attention to speciﬁc diseases related to infertility and
multivariate models. For now, ovarian reserve tests shall be
used as complementary tools in counseling processes, which
must be based on age and individuality. Associated with
variables such as the characteristics and conservation of the
gametes, the fertilization technique used, seminal quality,
embryo conservation and evolution, and the characteristics
of the endometrial cavity and of the pelvic-peritonealISRN Obstetrics and Gynecology 7
microenvironment, ovarian reserve tests may provide the
necessary information for the formulation of appropriate
stimulation protocols for each couple, reducing both
emotional and ﬁnancial burdens.
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